Thus, the finding that BRAFi/diclofenac combinations exert a potent anti-tumour activity even at very low BRAFi doses in both PTC and ATC BRAF-mutated cell lines (Fig. 7a–f) strongly suggests the possibility to delay—or reduce—the onset of acquired resistance, limiting the risk of unwanted effects. This evidence concerns the gene BRAF and neoplasm.